Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
28 févr. 2023 16h05 HE
|
Lumos Pharma, Inc.
Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled Primary Outcome Data for Both OraGrowtH Trials Expected 4Q 2023 AUSTIN, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lumos...
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
12 déc. 2022 07h30 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the...
Folia Health Technology Platform Used in First-of-its-Kind Real World Evidence Study for Sickle Cell Disease
15 sept. 2022 15h23 HE
|
Folia Health
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Today, Folia Health announced the initiation of the ASCEND Study, a first-of-its-kind, at-home observational real-world evidence study in which people...